Total trials
145
Active
21
Phase 3
58
Total enrollment
37,541
Pipeline matrix
Showing 20 of 20 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| IgPro10 | — | — | — | 5 | |||
| Garadacimab | — | — | — | — | 2 | ||
| CE1226 | — | — | — | — | — | 1 | |
| CSL222 | — | — | — | — | — | 2 | |
| CSL300 | — | — | — | — | 2 | ||
| IgPro20 | — | — | — | 8 | |||
| BE1116 | — | — | — | — | — | 3 | |
| Cryoprecipitate | — | — | — | — | — | 2 | |
| CSL511 Fibrinogen concentrate | — | — | — | — | — | 1 | |
| Recombinant single-chain factor VIII | — | — | — | — | — | 1 | |
| Recombinant fusion protein linking coagulation factor IX with albumin | — | — | — | — | — | 1 | |
| FFP | — | — | — | — | — | 1 | |
| CSL889 | — | — | — | — | 2 | ||
| Vamifeport | — | — | — | — | 2 | ||
| CSL787 | — | — | — | — | 2 | ||
| Anumigilimab | — | — | — | — | — | 1 | |
| AAV5-hFIXco-Padua | — | — | — | 3 | |||
| Factor IX | — | — | — | — | 2 | ||
| Hizentra | — | — | — | — | — | 1 | |
| HEMGENIX | — | — | — | — | — | 1 |
Next readouts
- 2026-06-23
- 2026-10-26
- 2026-11-18
- 2026-12-01
- 2027-08-30
- 2027-09-01
- 2027-10-22
- 2027-12
- 2028-02-28
- 2028-03-06
Top conditions
- Hemophilia B14
- Von Willebrand Disease7
- Hemophilia A7
- Primary Immune Deficiency6
- Hereditary Angioedema6
- Hereditary Angioedema Types I and II5
- Common Variable Immunodeficiency5
- Healthy Volunteers4
Frequently asked questions about CSL Behring
- How many clinical trials does CSL Behring have on ClinicalTrials.gov?
- CSL Behring is listed as the lead sponsor on 145 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of CSL Behring's trials are in Phase 3?
- 58 of CSL Behring's trials are in Phase 3, spread across 20 active drug programs.
- What therapeutic areas does CSL Behring focus on?
- CSL Behring's most-studied conditions on ClinicalTrials.gov are Hemophilia B, Von Willebrand Disease, Hemophilia A, Primary Immune Deficiency, Hereditary Angioedema.
- When are CSL Behring's next clinical trial readouts?
- CSL Behring has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab”, expected around 2026-06-23.